Georgios I. Tagarakis

Prof. Dr. Georgios I. Tagarakis

Cardiothoracic Surgery Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2012 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
GTGeorgios I. Tagarakis
Georgios I. Tagarakis
CVChristos Voucharas
Christos Voucharas
FTFani Tsolaki
Fani Tsolaki
MDMarios E Daskalopoulos
Marios E Daskalopoulos
Vasileios PapaliagkasVasileios Papaliagkas
Vasileios Papaliagkas
NTNikolaos B Tsilimingas
Nikolaos B Tsilimingas
To investigate the controlling efficacy of ondasetron and haloperidol in regard to the postcardiotomy delirium.

26 November 2023 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
Eleni KarlaftiEleni Karlafti
Eleni Karlafti
DTDimitrios Tsavdaris
Dimitrios Tsavdaris
Evangelia KotzakioulafiEvangelia Kotzakioulafi
Evangelia Kotzakioulafi
LKLeonidas Kougias
Leonidas Kougias
GTGeorgios I. Tagarakis
Georgios I. Tagarakis
Daniel ParamythiotisDaniel Paramythiotis
Daniel Paramythiotis
Introduction: Hemoptysis is one of the most common symptoms of respiratory system diseases. Common causes include bronchiectasis, tumors, tuberculosis, aspergilloma, and cystic fibrosis. The severity of hemoptysis varies from mild to moderate to massive hemoptysis and can easily lead to hemodynamic instability and death from suffocation or shock. Nevertheless, the most threatening hemoptysis that is presented to the emergency department and requires hospitalization is the massive one. In these cases, today, the most common way to manage hemoptysis is bronchial artery embolization (BAE). Methods: A systematic literature search was conducted in PubMed and Scopus from January 2017 (with the aim of selecting the newest possible reports in the literature) until May 2023 for studies reporting massive hemoptysis. All studies that included technical and clinical success rates of hemoptysis management, as well as rebleeding and mortality rates, were included. A proportional meta-analysis was conducted using a random-effects model. Results: Of the 30 studies included in this systematic review, 26 used bronchial artery embolization as a means of treating hemoptysis, with very high levels of both technical and clinical success (greater than 73.7% and 84.2%, respectively). However, in cases where it was not possible to use bronchial artery embolization, alternative methods were used, such as dual-vessel intervention (80% technical success rate and 66.7% clinical success rate), customized endobronchial silicone blockers (92.3% technical success rate and 92.3% clinical success rate), antifibrinolytic agents (50% clinical success rate), and percutaneous transthoracic embolization (93.1% technical success rate and 88.9% clinical success rate), which all had high success rates apart from antifibrinolytic agents. Of the 2467 patients included in these studies, 341 experienced rebleeding during the follow-up period, while 354 other complications occurred, including chest discomfort, fever, dysphagia, and paresis. A total of 89 patients died after an episode of massive hemoptysis or during the follow-up period. The results of the meta-analysis showed a pooled technical success of bronchial artery embolization equal to 97.22% and a pooled clinical success equal to 92.46%. The pooled recurrence was calculated to be 21.46%, while the mortality was 3.5%. These results confirm the ability of bronchial artery embolization in the treatment of massive hemoptysis but also emphasize the high rate of recurrence following the intervention, as well as the risk of death. Conclusion: In conclusion, massive hemoptysis can be treated with great clinical and technical success using bronchial artery embolization, reducing mortality. Mortality has now been reduced to a small percentage of cases.

31 January 2014 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
GTGeorgios I. Tagarakis
Georgios I. Tagarakis
IAIsaac Aidonidis
Isaac Aidonidis
SDStella Daskalopoulou
Stella Daskalopoulou
VSVassilios Simopoulos
Vassilios Simopoulos
VLVassilios Liouras
Vassilios Liouras
NTNikolaos Tsilimingas
Nikolaos Tsilimingas
Background/Objective: Ranolazine is a new anti-ischemic agent approved for chronic angina with additional electrophysiologic properties. The purpose of the present trial was to investigate its effect in preventing postoperative atrial fibrillation (POAF) after on-pump coronary artery bypass graft (CABG) surgery. Methods: In the current prospective, randomized, (1 active: 2 control), single-blind (outcome assessors), single-centre clinical trial we recruited consecutive eligible patients scheduled for elective on-pump CABG. Participants were assigned to receive either oral ranolazine 375 mg twice daily for 3 days prior to surgery and until discharge, or to receive usual care. Patients were monitored for the development of POAF. Results: We enrolled 102 patients. Significantly lower incidence of POAF was noted in the ranolazine group compared with the control group (3 out of 34 patients, 8.8%, vs 21 out of 68 patients, 30.8%; p< 0.001). Mean values of left atrial diameter and left ventricular ejection fraction between the control and the ranolazine group were not significantly different. Conclusion: Our findings suggest a protective role of oral ranolazine when administered in a moderate dose preoperatively in patients undergoing on-pump CABG surgery. Future studies based on a wider sample of patients will eventually support our conclusions.

15 December 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
GAGeorgios Afxonidis
Georgios Afxonidis
Dimitrios V. MoysidisDimitrios V. Moysidis
Dimitrios V. Moysidis
APAndreas S Papazoglou
Andreas S Papazoglou
Christos TsagkarisChristos Tsagkaris
Christos Tsagkaris
ALAnna Loudovikou
Anna Loudovikou
KAKyriakos Anastasiadis
Kyriakos Anastasiadis
Background: This randomized controlled trial aimed to investigate the influence of physical activity and respiratory physiotherapy on zero postoperative day on clinical, hemodynamic and respiratory parameters of patients undergoing cardiac surgeries under extracorporeal circulation. Methods: 78 patients undergoing coronary artery bypass graft (CABG) or/and valvular heart disease surgeries were randomly assigned into an early and enhanced physiotherapy care group (EEPC group; n = 39) and a conventional physiotherapy care group (CPC group; n = 39). Treatment protocol for the EEPC group included ≤3 Mets of physical activity and respiratory physiotherapy on zero post-operative day and an extra physiotherapy session during the first three post-operative days, whereas the CPC group was treated with usual physiotherapy care after the first post-operative day. The length of hospital and intensive care unit (ICU) stay were set as the primary study outcomes, while pre- and post-intervention measurements were also performed to assess the oxymetric and hemodynamic influence of early mobilization and physiotherapy. Results: Participants’ mean age was 51.9 ± 13.8 years. Of them 48 (61.5%) underwent CABG. Baseline and peri-procedural characteristics did not differ between the two groups. The total duration of hospital and ICU stay were significantly higher in the CPC group compared to the EEPC group (8.1 ± 0.4 days versus 8.9 ± 0.6 days and 25.4 ± 3 h versus 23.2 ± 0.6 h, p < 0.001, respectively). Statistically significant differences in pre-intervention oxygen saturation, and post-intervention PO2 and lactate levels were also observed between the two groups (p = 0.022, 0.027 and 0.001, respectively). Conclusion: In on-pump cardiac surgery, early and enhanced post-procedural physical activity (≤3 METS) can prevent a prolonged ICU stay and decrease the duration of hospitalization while ameliorating post-operative hemodynamic and oxymetric parameters.

17 August 2010 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
Dimos KarangelisDimos Karangelis
Dimos Karangelis
GTGeorgios I. Tagarakis
Georgios I. Tagarakis
MDMarios Daskalopoulos
Marios Daskalopoulos
GSGeorgios Skoumis
Georgios Skoumis
NDNicholaos Desimonas
Nicholaos Desimonas
NTNikolaos B Tsilimingas
Nikolaos B Tsilimingas
The aim of the present study was to evaluate the efficacy of autologous blood pleurodesis in the management of persistent air leak in spontaneous pneumothorax. A number of 15 patients (10 male and 5 female) were included in this prospective study between March 2005 and December 2009. The duration of the air leak exceeded 7 days in all patients. The application of blood pleurodesis was used as the last preoperative conservative method of treatment in 12 patients. One patient refused surgery and two were ineligible for operation due to their comorbidities. A blood sample of 50 ml was obtained from the patient's femoral vein and immediately introduced into the chest tube. A success rate of 27% was observed having the air leak sealed in 4 patients in less than 24 hours. Despite our disappointingly poor outcome, the authors believe that the procedure's safety, convenience and low cost establish it as a worth trying method of conservative treatment for patients with the aforementioned pathology for whom no other alternative than surgery would be a choice.

3 September 2022 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
MPMary Panagidi
Mary Panagidi
ΑPΑndreas S. Papazoglou
Αndreas S. Papazoglou
DMDimitrios V. Moysidis
Dimitrios V. Moysidis
EVElpiniki Vlachopoulou
Elpiniki Vlachopoulou
MPMarios Papadakis
Marios Papadakis
KAKyriakos Anastasiadis
Kyriakos Anastasiadis
Objectives: Phase angle (PA) constitutes a bioelectrical impedance measurement, indicating cell membrane health and integrity, hydration, and nutritional status. Handgrip strength (HS) has been also associated with body composition, nutritional status, inflammation, and functional ability in several chronic diseases. Although their prognostic significance as independent biomarkers has been already investigated regarding the outcomes of a cardiac surgery, our study is the first one to assess the combined predictive value of preoperative PA and HS. Design and methods: HS and PA measurements were performed preoperativelyin 195 patients undergoing cardiac surgery. The association ofthe combination of HS and PAwith all-cause mortality rates was the primary study outcome, while its association with the intensive care unit (ICU) length of stay (LOS) was the secondary one. Results: PA was positively correlated with HS (r = 0.446, p < 0.005) and negatively with EuroSCORE II (r = − 0.306 p < 0.005). The combination of PA < 5.15 and HS < 25.5 was associated with higher one-year all-cause mortality (OR = 9.28; 95% CI 2.50–34.45; p = 0.001) compared to patients with PA > 5.15 and HS > 25.5, respectively. Patients with combined lower values of PA and HS (PA < 5.15 and HS < 30.7) were at higher risk of prolonged ICU LOS (OR = 4.02; 95% CI 1.53–10.56; p = 0.005) compared to those with higher PA–HS (PA > 5.15–HS > 30.7). The combination of PA–HS was also significantly linked with EuroSCORE II. Conclusion: The combination of low preoperative PA and HS values was significantly associated with higher risk of all-cause mortality at 12 months and prolonged ICU LOS; thereby it might serve as a clinically useful prognostic biomarker after cardiac surgery procedures.